Tiotropium in chronic obstructive pulmonary disease [5]

New England Journal of Medicine

Volumn 360, Issue 2, 2009, Pages 186-187

  Sierra Sánchez Sr , Jesús F ^a   Alegre del Rey Sr , Emilio J ^a   Cobo Sr , Isidoro ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SCOPOLAMINE DERIVATIVE;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; FOLLOW UP; HUMAN; LETTER; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; DRUG COMBINATION; EPIDEMIOLOGY; META ANALYSIS; NOTE; CAUSE OF DEATH; CHEMICALLY INDUCED DISORDER; LUNG TUMOR; URINE RETENTION;

BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; META-ANALYSIS AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SELECTION BIAS; CAUSE OF DEATH; LUNG NEOPLASMS; URINARY RETENTION;

EID: 58149394163     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50.